Global $94B+ Vaccines Market Outlook, 2024-2030 by Type, Technology, Indication, Route of Administration, Age Group and Region - Rising Need for DPT Vaccine for Protection Against Serious Respiratory Ailments
08 mai 2024 03h50 HE
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA...
Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis, 2023-2030, Featuring Profiles of GSK, Novavax, SPI Pharma (Associated British Foods), Agenus, and CSL Among Others
10 avr. 2024 04h05 HE
|
Research and Markets
Dublin, April 10, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis, 2023-2030" report has been added to ResearchAndMarkets.com's offering.The...
mRNA Platform Global Strategic Research Report 2024
05 avr. 2024 09h17 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The report delves into the mRNA...
BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten
11 mars 2024 07h45 HE
|
BioNTech SE
MAINZ, Deutschland, 11. März 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom...
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
11 mars 2024 07h45 HE
|
BioNTech SE
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association...
mRNA Vaccines in the Global Infectious Diseases Market: Opportunities, Challenges, Unmet Needs, Current Companies and Market Outlook
04 mars 2024 11h54 HE
|
Research and Markets
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines in Infectious Diseases Market Overview" report has been added to ResearchAndMarkets.com's offering.The report provides an assessment of...
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
28 sept. 2023 12h24 HE
|
BioNTech SE
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a...
BioNTech und CEPI geben Partnerschaft zur Entwicklung eines mRNA-Mpox-Impfstoffs und zur Unterstützung von CEPIs 100-Tage-Ziel bekannt
18 sept. 2023 06h45 HE
|
BioNTech SE
BioNTech bereitet klinische Phase-1/2-Studie für das mRNA-basierte Mpox-Impfstoffprogramm BNT166 vorDie Coalition for Epidemic Preparedness Innovations (CEPI) stellt bis zu 90 Millionen US-Dollar für...
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
18 sept. 2023 06h45 HE
|
BioNTech SE
BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
30 août 2023 10h00 HE
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical data...